Straits Times Index
3,313.48 +8.49 (+0.26%) Nikkei
38,787.38 -132.88 (-0.34%) Hang Seng
19,553.61 +177.08 (+0.91%) FTSE 100
8,420.26 -18.39 (-0.22%) Bitcoin USD
66,907.77 -72.51 (-0.11%) CMC Crypto 200
1,364.49 -9.36 (-0.68%)
DURECT Corporation (DRRX)
After hours:
| Previous close | 0.9438 |
| Open | 0.9700 |
| Bid | 0.9021 x 100 |
| Ask | 0.9742 x 100 |
| Day's range | 0.8899 - 0.9700 |
| 52-week range | 0.4700 - 7.4600 |
| Volume | |
| Avg. volume | 139,022 |
| Market cap | 28.867M |
| Beta (5Y monthly) | 0.93 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update
DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2024 and provided a business update.
- PR Newswire
DURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business Update
DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the company will report its first quarter financial results on Monday, May 13, 2024. Management will also host a conference call and webcast with investors to discuss financial results and provide a corporate update at 4:30 pm Eastern Time. D
- PR Newswire
DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis
DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury and cancer, today announced acceptance of a late-breaking oral presentation at the European Association for the Study of the Liver (EASL) Congress 2024 to take place June 5-8, 2024 in Milan, Italy. The presentation will discuss data from the Company's Phase 2b AHFIRM trial, whi
